Literature DB >> 20451945

Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy.

Binshan Shi1, Christina Kitchen, Barbara Weiser, Douglas Mayers, Brian Foley, Kimdar Kemal, Kathryn Anastos, Marc Suchard, Monica Parker, Cheryl Brunner, Harold Burger.   

Abstract

Characterization of residual plasma virus during antiretroviral therapy (ART) is a high priority to improve understanding of HIV-1 pathogenesis and therapy. To understand the evolution of HIV-1 pol and env genes in viremic patients under selective pressure of ART, we performed longitudinal analyses of plasma-derived pol and env sequences from single HIV-1 genomes. We tested the hypotheses that drug resistance in pol was unrelated to changes in coreceptor usage (tropism), and that recombination played a role in evolution of viral strains. Recombinants were identified by using Bayesian and other computational methods. High-level genotypic resistance was seen in approximately 70% of X4 and R5 strains during ART. There was no significant association between resistance and tropism. Each patient displayed at least one recombinant encompassing env and representing a change in predicted tropism. These data suggest that, in addition to mutation, recombination can play a significant role in shaping HIV-1 evolution. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20451945      PMCID: PMC3186207          DOI: 10.1016/j.virol.2010.04.008

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  87 in total

1.  Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy.

Authors:  Maria Pia De Pasquale; Andrew J Leigh Brown; Susan Cu Uvin; Jessica Allega-Ingersoll; Angela M Caliendo; Lorraine Sutton; Shannon Donahue; Richard T D'Aquila
Journal:  J Acquir Immune Defic Syndr       Date:  2003-09-01       Impact factor: 3.731

2.  Evolution of R5 and X4 human immunodeficiency virus type 1 gag sequences in vivo: evidence for recombination.

Authors:  Ronald P van Rij; Michael Worobey; Janny A Visser; Hanneke Schuitemaker
Journal:  Virology       Date:  2003-09-15       Impact factor: 3.616

3.  Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy.

Authors:  Seble Kassaye; Elizabeth Johnston; Bryan McColgan; Rami Kantor; Lynn Zijenah; David Katzenstein
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

4.  Evolution of CCR5 use before and during coreceptor switching.

Authors:  Mia Coetzer; Rebecca Nedellec; Janelle Salkowitz; Sherry McLaughlin; Yi Liu; Laura Heath; James I Mullins; Donald E Mosier
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

Review 5.  Coreceptor switch in infection of nonhuman primates.

Authors:  Cecilia Cheng-Mayer; Silvana Tasca; Siu-hong Ho
Journal:  Curr HIV Res       Date:  2009-01       Impact factor: 1.581

Review 6.  Eradication of HIV: current challenges and new directions.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  J Antimicrob Chemother       Date:  2008-11-04       Impact factor: 5.790

7.  Potential limitation of CCR5 antagonists: drug resistance more often linked to CXCR4-utilizing than to CCR5-utilizing HIV-1.

Authors:  Thor A Wagner; Lisa M Frenkel
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177

8.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.

Authors:  Sarah Palmer; Frank Maldarelli; Ann Wiegand; Barry Bernstein; George J Hanna; Scott C Brun; Dale J Kempf; John W Mellors; John M Coffin; Martin S King
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-10       Impact factor: 11.205

9.  Multiple-infection and recombination in HIV-1 within a longitudinal cohort of women.

Authors:  Alan R Templeton; Melissa G Kramer; Joseph Jarvis; Jeanne Kowalski; Stephen Gange; Michael F Schneider; Qiujia Shao; Guang Wen Zhang; Mei-Fen Yeh; Hua-Ling Tsai; Hong Zhang; Richard B Markham
Journal:  Retrovirology       Date:  2009-06-03       Impact factor: 4.602

Review 10.  Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection.

Authors:  Lin Shen; Robert F Siliciano
Journal:  J Allergy Clin Immunol       Date:  2008-07       Impact factor: 10.793

View more
  18 in total

1.  Recombination between variants from genital tract and plasma: evolution of multidrug-resistant HIV type 1.

Authors:  Kimdar S Kemal; Christina M Ramirez; Harold Burger; Brian Foley; Douglas Mayers; Thomas Klimkait; François Hamy; Kathryn Anastos; Katarina Petrovic; Vladimir N Minin; Marc A Suchard; Barbara Weiser
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-10       Impact factor: 2.205

2.  A novel denaturing heteroduplex tracking assay for genotypic prediction of HIV-1 tropism.

Authors:  Binshan Shi; Barbara Weiser; Linda M Styer; Kimdar Kemal; Cheryl Brunner; Kathryn Anastos; Harold Burger
Journal:  J Virol Methods       Date:  2012-06-21       Impact factor: 2.014

3.  Identifying recombination hot spots in the HIV-1 genome.

Authors:  Redmond P Smyth; Timothy E Schlub; Andrew J Grimm; Caryll Waugh; Paula Ellenberg; Abha Chopra; Simon Mallal; Deborah Cromer; Johnson Mak; Miles P Davenport
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

4.  Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors.

Authors:  Richard J P Brown; Paul J Peters; Catherine Caron; Maria Paz Gonzalez-Perez; Leanne Stones; Chiambah Ankghuambom; Kemebradikumo Pondei; C Patrick McClure; George Alemnji; Stephen Taylor; Paul M Sharp; Paul R Clapham; Jonathan K Ball
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

5.  High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia.

Authors:  Rebecca Nedellec; Joshua T Herbeck; Peter W Hunt; Steven G Deeks; James I Mullins; Elizabeth D Anton; Jacqueline D Reeves; Donald E Mosier
Journal:  AIDS Res Hum Retroviruses       Date:  2016-10-12       Impact factor: 2.205

Review 6.  The emergence of drug resistant HIV variants and novel anti-retroviral therapy.

Authors:  Koosha Paydary; Parisa Khaghani; Sahra Emamzadeh-Fard; Seyed Ahmad Seyed Alinaghi; Kazem Baesi
Journal:  Asian Pac J Trop Biomed       Date:  2013-07

Review 7.  HIV-1 Reservoirs During Suppressive Therapy.

Authors:  Kirston Barton; Anni Winckelmann; Sarah Palmer
Journal:  Trends Microbiol       Date:  2016-02-12       Impact factor: 17.079

8.  Molecular epidemiology of HIV type 1 subtypes in Rwanda.

Authors:  Kimdar S Kemal; Kathryn Anastos; Barbara Weiser; Christina M Ramirez; Qiuhu Shi; Harold Burger
Journal:  AIDS Res Hum Retroviruses       Date:  2013-04-01       Impact factor: 2.205

9.  Single genome amplification of proviral HIV-1 DNA from dried blood spot specimens collected during early infant screening programs in Lusaka, Zambia.

Authors:  Lillian Seu; Innocent Mwape; M Bradford Guffey
Journal:  J Virol Methods       Date:  2014-03-22       Impact factor: 2.014

10.  Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations.

Authors:  Mark A Winters; Robert M Lloyd; Robert W Shafer; Michael J Kozal; Michael D Miller; Mark Holodniy
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.